Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies.

Protein aggregation in biotherapeutics has been identified to increase immunogenicity, leading to immune-mediated adverse effects, such as severe allergic responses including anaphylaxis. The induction of anti-drug antibodies (ADAs) moreover enhances drug clearance rates, and can directly block therapeutic function. In this review, identified immune activation mechanisms triggered by protein aggregates are discussed, as well as physicochemical properties of aggregates, such as size and shape, which contribute to immunogenicity. Furthermore, factors which contribute to protein stability and aggregation are considered. Lastly, with these factors in mind, we encourage an innovative and multidisciplinary approach with regard to further research in the field, with the overall aim to avoid immunogenic aggregation in future drug development.

Inorganic nanoparticles as potential regulators of immune response in dendritic cells.

AIM: The spontaneous adsorption of proteins on nanoparticles (NPs) in biological media is exploited to prepare complexes of NPs and proteins from cancer cells' lysates for application in cancer immunotherapy. MATERIALS & METHODS: Gold (Au) and silica NPs were synthesized, incubated with cancer cells' lysates and characterized. Dendritic cells (DCs) were challenged with protein-coated NPs, their maturation, viability and morphology were evaluated and lymphocytes T proliferation was determined. RESULTS: Silica and Au NPs bound different pools of biomolecules from lysates, and are therefore promising selective carriers for antigens. When incubated with immature DCs, NPs were efficiently endocytosed without cytotoxicity. Finally, protein-coated AuNPs promoted DC maturation and DC-mediated lymphocyte proliferation, at variance with lysate alone and protein-coated silica NPs, that did not promote DCs maturation. CONCLUSION: These results demonstrate that the spontaneous formation of protein coronas on NPs represents a possible approach to fast, easy, cost-effective DCs stimulation.

Magnetic field responsive drug release from magnetoliposomes in biological fluids.

The final fate of nano-scaled drug delivery systems into the body is highly affected by their interaction with proteins in biological fluids (serum, plasma, etc.). Nanocarriers dispersed in biological fluids bear a protein "corona" that covers their surface. Thus, it is extremely important to evaluate the drug release efficiency also in the biological environment where protein-nanocarrier complexes are formed. The purpose of this work is to determine how drug release from lipid vesicle carriers is influenced by the interaction with serum proteins, highlighting the importance to test the effectiveness of such systems in the biological milieu. In particular, this paper describes the magnetically triggered release behaviour of magnetoliposomes (MLs) dispersed both in aqueous physiological buffer and in bovine serum at two different concentrations (10% and 55% v/v) upon exposure to a low-frequency alternating magnetic field (LF-AMF). We studied the release from MLs loaded with two types of magnetic nanoparticles (MNPs): citrate coated Fe3O4 and oleic acid coated γ-Fe2O3. The permeability in the above-mentioned fluids was evaluated in terms of the fluorescence self-quenching of carboxyfluorescein (CF) entrapped inside the liposome aqueous pool. The results showed a strong reduction of the release in biological fluids, in particular at high serum concentration. We related this decrease to the formation of protein-liposome complexes that, under LF-AMF exposure, are subjected to destabilization and tend to form aggregates. Our results clearly highlight the importance of testing the release efficiency of self-assembled drug delivery systems in biological fluids, in order to understand their behaviour in the presence of proteins and biomolecules.